Recently, in vitro and in vivo studies have suggested that Type-I interferon (IFN), including IFN-α and IFN-β, stimulates cross-priming by DC against tumor-associated antigens is a key mechanism for cancer immune surveillance and can be targeted to boost anti-tumor CD8+ T-cell responses8. The gene discussed is CD8A; the disease is neoplasm.